Pediatrix Medical Group, Inc.
Close on Oct 19, 2026
- Market cap
- $2.22B
- P/E (TTM)
- 13.1
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 15, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $476.20M | $0.36 | $0.44 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | Before market open | $493.80M | $0.40 | $0.50 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $492.90M | $0.84 | $0.67 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $468.80M | $0.46 | $0.53 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $458.40M | $0.24 | $0.33 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 1, 2024 | Before market open | $511.20M | $0.23 | $0.44 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 15, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full year 2026 | $280.00M to $300.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Pediatrix Medical filed with the SEC
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer and Treasurer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Executive Vice President, Chief Financial Officer & Treasurer
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Pediatrix Announces Strategic Initiatives For
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Pediatrix Medical Group, Inc. (NYSE:MD) Supplemental Disclosure May 30, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99.1 to Form 8-K
Senior Vice President, Finance and Strategy
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99 to Form 8-K
Senior Vice President, Finance and Strategy
Results of operations · EX-99 to Form 8-K